Caffeic Acid Phenethyl Ester Loaded PLGA Nanoparticles: Effect of Various Process Parameters on Reaction Yield, Encapsulation Efficiency, and Particle Size

Journal of Nanomaterials

Volumn 2015, Issue , 2015, Pages

  Derman, Serap ^a  

^a YILDIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

EFFICIENCY; EMULSIFICATION; ENCAPSULATION; NANOPARTICLES; PARTICLE SIZE; PH;

CAFFEIC ACID PHENETHYL ESTER; ENCAPSULATION EFFICIENCY; OPTIMIZATION OF PROCESS PARAMETERS; PARTICLE SIZE AND SURFACES; POLYDISPERSITY INDICES; PROCESS PARAMETERS; PROCESSING PARAMETERS; SURFACTANT CONCENTRATIONS;

PARTICLE SIZE ANALYSIS;

EID: 84944212572     PISSN: 16874110     EISSN: 16874129     Source Type: Journal    
DOI: 10.1155/2015/341848     Document Type: Article

References (57)

1. H.-Y. Lee, Y.-I. Jeong, E. J. Kimet al. , "Preparation of caffeic acid phenethyl ester-incorporated nanoparticles and their biological activity," Journal of Pharmaceutical Sciences, vol. 104, no. 1, pp. 144-154, 2015.
2. M. R. Fesen, Y. Pommier, F. Leteurtre, S. Hiroguchi, J. Yung, and K. W. Kohn, "Inhibition of HIV-1 integrase by flavones, caffeic acid phenethyl ester (CAPE) and related compounds," Biochemical Pharmacology, vol. 48, no. 3, pp. 595-608, 1994.
3. G. F. Sud'Ina, O. K. Mirzoeva, M. A. Pushkareva, G. A. Korshunova, N. V. Sumbatyan, and S. D. Varfolomeev, "Caffeic acid phenethyl ester as a lipoxygenase inhibitor with antioxidant properties," FEBS Letters, vol. 329, no. 1-2, pp. 21-24, 1993.
4. S.-G. Park,D.-Y. Lee, S.-K. Seo et al. , "Evaluation of anti-allergic properties of caffeic acid phenethyl ester in a murine model of systemic anaphylaxis," Toxicology and Applied Pharmacology, vol. 226, no. 1, pp. 22-29, 2008.
5. Y.-J. Chen,M.-S. Shiao, and S.-Y. Wang, "Theantioxidant caffeic acid phenethyl ester induces apoptosis associated with selective scavenging of hydrogen peroxide in human leukemic HL-60 cells," Anti-Cancer Drugs, vol. 12, no. 2, pp. 143-149, 2001.
6. P. Michaluart, J. L. Masferrer, A. M. Carothers et al. , "Inhibitory effects of caffeic acid phenethyl ester on the activity and expression of cyclooxygenase-2 in human oral epithelial cells and in a rat model of inflammation," Cancer Research, vol. 59, no. 10, pp. 2347-2352, 1999.
7. M. Kartal, S. Yildiz, S. Kaya, S. Kurucu, andG. Topçu, "Antimicrobial activity of propolis samples from two different regions of Anatolia," Journal of Ethnopharmacology, vol. 86, no. 1, pp. 69-73, 2003.
8. J. H. Park, J. K. Lee, H. S. Kimet al. , "Immunomodulatory effect of caffeic acid phenethyl ester in Balb/c mice," International Immunopharmacology, vol. 4, no. 3, pp. 429-436, 2004.
9. J. Wu, C. Omene, J. Karkoszka et al. , "Caffeic acid phenethyl ester (CAPE), derived from a honeybee product propolis, exhibits a diversity of anti-tumor effects in pre-clinical models of human breast cancer," Cancer Letters, vol. 308, no. 1, pp. 43-53, 2011.
10. H.-F. Liao, Y.-Y. Chen, J.-J. Liu et al. , "Inhibitory effect of caffeic acid phenethyl ester on angiogenesis, tumor invasion, andmetastasis," Journal of Agricultural and Food Chemistry, vol. 51, no. 27, pp. 7907-7912, 2003.
11. A. Ilhan, U. Koltuksuz, S. Ozen, E. Uz, H. Ciralik, and O. Akyol, "The effects of caffeic acid phenethyl ester (CAPE) on spinal cord ischemia/reperfusion injury in rabbits," European Journal of Cardio-Thoracic Surgery, vol. 16, no. 4, pp. 458-463, 1999.
12. T. R. Burke Jr. ,M. R. Fesen, A. Mazumder et al. , "Hydroxylated aromatic inhibitors of HIV-1 integrase," Journal of Medicinal Chemistry, vol. 38, no. 21, pp. 4171-4178, 1995.
13. M. Watabe, K. Hishikawa, A. Takayanagi, N. Shimizu, and T. Nakaki, "Caffeic acid phenethyl ester induces apoptosis by inhibition of NFB and activation of Fas in human breast cancer MCF-7 cells," Journal of Biological Chemistry, vol. 279, no. 7, pp. 6017-6026, 2004.
14. K. Choi, Y.-H. Han, and C. Choi, "N-acetyl cysteine and caffeic acid phenethyl ester sensitize astrocytoma cells to Fas-mediated cell death in a redox-dependent manner," Cancer Letters, vol. 257, no. 1, pp. 79-86, 2007.
15. N. Berger, H. Ben Bassat, B. Y. Klein, and R. Laskov, "Cytotoxicity of NF-B inhibitors Bay 11-7085 and caffeic acid phenethyl ester to Ramos and other human B-lymphoma cell lines," Experimental Hematology, vol. 35, no. 10, pp. 1495-1509, 2007.
16. K. McEleny, R. Coffey, C. Morrissey, J. M. Fitzpatrick, and R. W. G. Watson, "Caffeic acid phenethyl ester-induced PC-3 cell apoptosis is caspase-dependent and mediated through the loss of inhibitors of apoptosis proteins," BJU International, vol. 94, no. 3, pp. 402-406, 2004.
17. U.-H. Jin, K.-H. Song, M. Motomura et al. , "Caffeic acid phenethyl ester induces mitochondria-mediated apoptosis in human myeloid leukemia U937 cells," Molecular and Cellular Biochemistry, vol. 310, no. 1-2, pp. 43-48, 2008.
18. T. Nagaoka, A. H. Banskota, Y. Tezuka et al. , "Inhibitory effects of caffeic acid phenethyl ester analogues on experimental lung metastasis of murine colon 26-L5 carcinoma cells," Biological and Pharmaceutical Bulletin, vol. 26, no. 5, pp. 638-641, 2003.
19. S. Gao and M. Hu, "Bioavailability challenges associated with development of anti-cancer phenolics," Mini-Reviews in Medicinal Chemistry, vol. 10, no. 6, pp. 550-567, 2010.
20. E. Kerns and L. Di, Drug-Like Properties: Concepts, Structure Design and Methods: From ADME to Toxicity Optimization, Academic Press, 2010.
21. Y.-C. Weng, S.-T. Chuang, Y.-C. Lin et al. , "Caffeic acid phenylethyl amide protects against the metabolic consequences in diabetes mellitus induced by diet and streptozocin," Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 984780, 12 pages, 2012.
22. X. Wang, J. Pang, J. A. Maffucci et al. , "Pharmacokinetics of caffeic acid phenethyl ester and its catechol-ring fluorinated derivative following intravenous administration to rats," Biopharmaceutics & Drug Disposition, vol. 30, no. 5, pp. 221-228, 2009.
23. A. Kumari, S. K. Yadav, and S. C. Yadav, "Biodegradable polymeric nanoparticles based drug delivery systems," Colloids and Surfaces B: Biointerfaces, vol. 75, no. 1, pp. 1-18, 2010.
24. A. Budhian, S. J. Siegel, and K. I. Winey, "Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content," International Journal of Pharmaceutics, vol. 336, no. 2, pp. 367-375, 2007.
25. D. K. Sahana, G. Mittal, V. Bhardwaj, and M. N. V. R. Kumar, "PLGA nanoparticles for oral delivery of hydrophobic drugs: Influence of organic solvent on nanoparticle formation and release behavior in vitro and in vivo using estradiol as a model drug," Journal of Pharmaceutical Sciences, vol. 97, no. 4, pp. 1530-1542, 2008.
26. B. N. Singh, S. Shankar, and R. K. Srivastava, "Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications," Biochemical Pharmacology, vol. 82, no. 12, pp. 1807-1821, 2011.
27. T. Chaowanachan, E. Krogstad, C. Ball, and K. A. Woodrow, "Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis," PLoS ONE, vol. 8, no. 4, Article ID e61416, 2013.
28. X. Song, Y. Zhao, S. Hou et al. , "Dual agents loaded PLGA nanoparticles: systematic study of particle size and drug entrapment efficiency," European Journal of Pharmaceutics and Biopharmaceutics, vol. 69, no. 2, pp. 445-453, 2008.
29. A. S. Hussein, N. Abdullah, and A. Fakru'l-Razi, "Optimizing the process parameters for encapsulation of linamarin into PLGAnanoparticles using doubleemulsion solvent evaporation technique,"Advances in Polymer Technology, vol. 32, supplement 1, pp. E486-E504, 2013.
30. S. Derman and Z. M. Akdeste, "Particle size and zeta potential investigation of synthetic peptide-protein conjugates," Turkish Journal of Biochemistry, vol. 40, no. 4, pp. 282-289, 2015.
31. M. Halayqa and U. Dománska, "PLGA biodegradable nanoparticles containing perphenazine or chlorpromazine hydrochloride: effect of formulation and release," International Journal of Molecular Sciences, vol. 15, no. 12, pp. 23909-23923, 2014.
32. S. Dixit, S. R. Singh, A. N. Yilma, R. D. Agee,M. Taha, and V. A. Dennis, "Poly(lactic acid)-poly(ethylene glycol) nanoparticles provide sustained delivery of a Chlamydia trachomatis recombinantMOMP peptide and potentiate systemic adaptive immune responses in mice,"Nanomedicine:Nanotechnology, Biology, and Medicine, vol. 10, no. 6, pp. 1311-1321, 2014.
33. E. Clelikkaya, E. B. DenkbasL, and E. PisLkin, "Rifampicin carrying poly (D, L-Lactide)/Poly(Ethylene Glycol) microspheres: loading and release," ArtificialOrgans, vol. 20,no. 7, pp. 743-751, 1996.
34. F. Esmaeili, M. Hosseini-Nasr, M. Rad-Malekshahi, N. Samadi, F. Atyabi, and R. Dinarvand, "Preparation and antibacterial activity evaluation of rifampicin-loaded poly lactide-coglycolide nanoparticles," Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 3, no. 2, pp. 161-167, 2007.
35. SPSS, SPSS for Windows Version 15. 0, SPSS, Chicago, Ill, USA, 2006.
36. S. Mao, J. Xu, C. Cai, O. Germershaus, A. Schaper, and T. Kissel, "Effect of WOW process parameters on morphology and burst release of FITC-dextran loaded PLGA microspheres," International Journal of Pharmaceutics, vol. 334, no. 1-2, pp. 137-148, 2007.
37. S. Mao, Y. Shi, L. Li, J. Xu, A. Schaper, and T. Kissel, "Effects of process and formulation parameters on characteristics and internal morphology of poly(d,l-lactide-co-glycolide) microspheres formed by the solvent evaporation method," European Journal of Pharmaceutics and Biopharmaceutics, vol. 68, no. 2, pp. 214-223, 2008.
38. R. Bodmeier and J. W. McGinity, "Polylactic acid microspheres containing quinidine base and quinidine sulphate prepared by the solvent evaporation technique. I. Methods and morphology," Journal of Microencapsulation, vol. 4, no. 4, pp. 279-288, 1987.
39. A. Al-Maaieh and D. R. Flanagan, "Salt and cosolvent effects on ionic drug loading into microspheres using an O/W method," Journal of Controlled Release, vol. 70, no. 1-2, pp. 169-181, 2001.
40. F. Boury, H. Marchais, J. E. Proust, and J. P. Benoit, "Bovine serum albumin release from poly(-hydroxy acid) microspheres: effects of polymer molecular weight and surface properties," Journal of Controlled Release, vol. 45, no. 1, pp. 75-86, 1997.
41. J. Panyam, D. William, A. Dash, D. Leslie-Pelecky, and V. Labhasetwar, "Solid-state solubility influences encapsulation and release of hydrophobic drugs from PLGA/PLA nanoparticles," Journal of Pharmaceutical Sciences, vol. 93, no. 7, pp. 1804-1814, 2004.
42. A. Kumar, H. M. Mansour, A. Friedman, and E. R. Blough, Nanomedicine in Drug Delivery, CRC Press, New York, NY, USA, 2013.
43. X. Song, Y. Zhao,W. Wu et al. , "PLGA nanoparticles simultaneously loaded with vincristine sulfate and verapamil hydrochloride: systematic study of particle size and drug entrapment efficiency," International Journal of Pharmaceutics, vol. 350, no. 1-2, pp. 320-329, 2008.
44. D. L. Cooper and S. Harirforoosh, "Design and optimization of PLGA-based diclofenac loaded nanoparticles," PLoS ONE, vol. 9, no. 1, Article IDe87326, 2014.
45. H.-Y. Kwon, J.-Y. Lee, S.-W. Choi, Y. Jang, and J.-H. Kim, "Preparation of PLGA nanoparticles containing estrogen by emulsification-diffusion method," Colloids and Surfaces A: Physicochemical and Engineering Aspects, vol. 182, no. 1-3, pp. 123-130, 2001.
46. M. Chorny, I. Fishbein, H. D. Danenberg, and G. Golomb, "Lipophilic drug loaded nanospheres prepared by nanoprecipitation: effect of formulation variables on size, drug recovery and release kinetics," Journal of Controlled Release, vol. 83, no. 3, pp. 389-400, 2002.
47. R. M. Mainardes and R. C. Evangelista, "PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution," International Journal of Pharmaceutics, vol. 290, no. 1-2, pp. 137-144, 2005.
48. B. Wang, G. Chen, Z. Mao, Y. Zhang, D. Yu, and C. Gao, "Preparation and cellular uptake of PLGA particles loaded with lamivudine," Chinese Science Bulletin, vol. 57, no. 31, pp. 3985-3993, 2012.
49. S. Galindo-Rodriguez, E. Allémann, H. Fessi, and E. Doelker, "Physicochemical parameters associated with nanoparticle formation in the salting-out, emulsification-diffusion, and nanoprecipitation methods," Pharmaceutical Research, vol. 21, no. 8, pp. 1428-1439, 2004.
50. A. P. Ranjan, A. Mukerjee, L. Helson, and J. K. Vishwanatha, "Scale up, optimization and stability analysis of Curcumin C3 complex-loaded nanoparticles for cancer therapy," Journal of Nanobiotechnology, vol. 10, article 38, 2012.
51. S. K. Sahoo, J. Panyam, S. Prabha, and V. Labhasetwar, "Residual polyvinyl alcohol associated with poly (D,L-lactide-coglycolide) nanoparticles affects their physical properties and cellular uptake," Journal of Controlled Release, vol. 82, no. 1, pp. 105-114, 2002.
52. T. Niwa,H. Takeuchi,T. Hino, N. Kunou, andY. Kawashima, "In vitro drug release behavior of D,L-lactide/glycolide copolymer (PLGA) nanospheres with nafarelin acetate prepared by a novel spontaneous emulsification solvent diffusion method," Journal of Pharmaceutical Sciences, vol. 83, no. 5, pp. 727-732, 1994.
53. R. Dangi and S. Shakya, "Preparation, optimization and characterization of PLGA nanoparticle," International Journal of Pharmacy & Life Sciences, vol. 4, no. 7, 2013.
54. M. Izadifar, M. E. Kelly, A. Haddadi, and X. Chen, "Optimization of nanoparticles for cardiovascular tissue engineering," Nanotechnology, vol. 26, no. 23, Article ID 235301, 2015.
55. I. G. Zigoneanu, C. E. Astete, and C. M. Sabliov, "Nanoparticles with entrapped -tocopherol: synthesis, characterization, and controlled release," Nanotechnology, vol. 19, no. 10, Article ID 105606, 2008.
56. H. Wang, Y. Zhao, Y. Wu et al. , "Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles," Biomaterials, vol. 32, no. 32, pp. 8281-8290, 2011.
57. P. Le Corre, P. Le Guevello, V. Gajan, F. Chevanne, and R. Le Verge, "Preparation and characterization of bupivacaineloaded polylactide and polylactide-co-glycolide microspheres," International Journal of Pharmaceutics, vol. 107, no. 1, pp. 41-49, 1994.